International Stem Cell Corporation, announced today its wholly-owned subsidiary, Lifeline Cell Technology (Lifeline), has signed a distribution agreement with Tokyo-based Veritas Corporation to distribute its human cell culture products throughout Japan.
Lifeline, located in Maryland and California, specializes in the development, manufacture, and distribution of products to culture human cells for the study of human disease, including products to culture primary human cells and human stem cells. These products are being requested by customers overseas, including customers in Japan, Korea and India and this agreement is the first step in Lifeline’s plan to meet these requests.
A have-a-go hero who was blinded in one eye in a chemical attack 15 years ago has miraculously got his sight back after undergoing pioneering stem cell treatment.
Russell Turnbull is one of eight patients with impaired vision who have been treated successfully with their own stem cells, in a technique developed by scientists and eye surgeons at the North East England Stem Cell Institute.
Mr Turnbull was hit in his right eye, causing massive damage to the cornea stem cells, leaving him with severely impaired vision, a condition known as Limbal Stem Cell Deficiency (LSCD) (…)
Image by Trygve.u via Flickr
Drs. Scott Kitchen, Zoran Galic, Jerry Zack of the UCLA Broad Stem Cell Research Center and AIDS Institute and their colleagues demonstrated for the first time that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells. The process could potentially be used against a range of chronic viral diseases.
The study, published Dec. 7 in the-peer reviewed online journal PLoS ONE, provides proof-of-principle, a demonstration of feasibility, that human stem cells can be engineered into the equivalent of a genetic vaccine.
“We have demonstrated in this proof-of-principle study that
Two scientists at the Fred Hutchinson Cancer Research Center in Seattle have been awarded $16.7 million for stem cell research projects.
Dr. Irwin Bernstein and Beverly Torok-Storb received the federal funding from the National Heart, Lung and Blood Institute. Their award is part of a $170 million effort divided among 18 scientific teams.
Torok-Storb will work with Dr. Mortimer Poncz of Children’s Hospital of Philadelphia to develop molecular and cell-based therapies for a range of blood diseases, using an $8.2 million grant.
Bernstein will work with Edward Morrisey of the University of Pennsylvania to study how biochemical reactions inside cells affect cell
A novel pathway of stem cell activity in human brain that represents potential targets of brain injuries affecting newborns has been identified by researchers at Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center. The recent study, which raises new questions of how the brain evolves, is published in the current issue of Nature, one of the world’s most cited scientific journals.
Nader Sanai, MD, director of Barrow’s Brain Tumor Research Center, led this study, which is the first developmental study of human neural stem cells in a region of the brain called the subventricular zone, the tissue structure